McCall, D., Roth, M., Mahadeo, K. M., Toepfer, L., Nunez, C., Short, N. J., … Cuglievan, B. (2021). Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. Blood Adv, 5(23), 5215–5219. https://doi.org/10.1182/bloodadvances.2021005164

McCall, David, Michael Roth, Kris M. Mahadeo, Laurie Toepfer, Cesar Nunez, Nicholas J. Short, Naval Daver, et al. “Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia.” Blood Adv 5, no. 23 (December 14, 2021): 5215–19. https://doi.org/10.1182/bloodadvances.2021005164.

McCall D, Roth M, Mahadeo KM, Toepfer L, Nunez C, Short NJ, et al. Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. Blood Adv. 2021 Dec 14;5(23):5215–9.

McCall, David, et al. “Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia.” Blood Adv, vol. 5, no. 23, Dec. 2021, pp. 5215–19. Pubmed, doi:10.1182/bloodadvances.2021005164.

McCall D, Roth M, Mahadeo KM, Toepfer L, Nunez C, Short NJ, Daver N, Kadia TM, DiNardo C, Yi JS, Cuglievan B. Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. Blood Adv. 2021 Dec 14;5(23):5215–5219.